Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JCR Pharmaceuticals CoTSE:4552 +0.57%46 Debt-to-Equity is 1.15 as of Mar. 2026, which is 195% above its 10-year median of 0.39. GuruFocus rates TSE:4552 with a GF Score™ of 46/100 and a GF Value™ of 円787.71 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 811 Drug Manufacturers companies, JCR Pharmaceuticals Co ranks worse than 90.63% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for JCR Pharmaceuticals Co's Debt-to-Equity or its related term are showing as below:
TSE:4552'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.18 Med: 0.39 Max: 1.15
Current: 1.25
During the past 13 years, the highest Debt-to-Equity Ratio of JCR Pharmaceuticals Co was 1.15. The lowest was 0.18. And the median was 0.39.
TSE:4552's Debt-to-Equity is ranked worse than 90.63% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs TSE:4552: 1.25
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
JCR Pharmaceuticals Co Debt-to-Equity Related Terms
JCR Pharmaceuticals Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for JCR Pharmaceuticals Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4552 vs LLY, JNJ, ABBV: Debt-to-Equity Comparison
For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JCR Pharmaceuticals Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where JCR Pharmaceuticals Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JCR Pharmaceuticals Co (TSE:4552) has a Debt-to-Equity of 1.15 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on JCR Pharmaceuticals Co and its competitors. This is 195% above median its historical median of 0.39. Over the past decade, JCR Pharmaceuticals Co's Debt-to-Equity has ranged from 0.18 to 1.15. According to the industry distribution chart, JCR Pharmaceuticals Co ranks #735 out of 811 companies in the Drug Manufacturers industry, placing it in the top 90.6%.
Is JCR Pharmaceuticals Co's Debt-to-Equity too high?
JCR Pharmaceuticals Co's current Debt-to-Equity of 1.15 is 195% above median its 10-year median of 0.39. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 1.15. The Drug Manufacturers industry median Debt-to-Equity is 0.28. JCR Pharmaceuticals Co's value of 1.15 is 310.7% above this industry median. Based on the distribution chart, JCR Pharmaceuticals Co ranks #735 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, JCR Pharmaceuticals Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JCR Pharmaceuticals Co's Debt-to-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, JCR Pharmaceuticals Co ranks #735 out of 811 companies for Debt-to-Equity. This places JCR Pharmaceuticals Co in the lower half of its industry. The industry median Debt-to-Equity is 0.28. JCR Pharmaceuticals Co's value of 1.15 is 310.7% above this benchmark. Historically, JCR Pharmaceuticals Co's own Debt-to-Equity has ranged from 0.18 to 1.15 over the past decade. While the company's 10-year median is 0.39 vs. the industry median of 0.28, JCR Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JCR Pharmaceuticals Co's current Debt-to-Equity of 1.15 is 310.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on JCR Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JCR Pharmaceuticals Co's current Debt-to-Equity is 1.15, which is 195% above median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JCR Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co (TSE:4552) is currently considered Possible Value Trap. The stock's GF Value™ is 円787.71, compared to a current price of 円528.00 — trading 33% below its estimated fair value. The current Debt-to-Equity is 1.15, which is 195% above median its 10-year median of 0.39 and 310.7% above the Drug Manufacturers industry median of 0.28. JCR Pharmaceuticals Co's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For JCR Pharmaceuticals Co (TSE:4552), the current Debt-to-Equity is 1.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JCR Pharmaceuticals Co (TSE:4552) Overvalued in 2026?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co stock appears to be undervalued.
The current stock price of 円528.00 is trading 33% below its estimated GF Value™ of 円787.71.
GuruFocus considers JCR Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for TSE:4552:
Debt-to-Equity: 1.15 (195% above median its 10-year median of 0.39)
GF Value™: 円787.71 vs. price of 円528.00 (33% below fair value)
Industry Position: 310.7% above the Drug Manufacturers median (#735 of 811)
No single metric tells the full story. See the TSE:4552 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
46GF Score
Get the complete analysis for TSE:4552
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4552 has been successfully added to your 
